As orders for company’s first tabletop testing device come in from customers around the world, company seeks additional $5-6 million (US)
TEL AVIV – June 11, 2018 /Canna Newswire/ – GemmaCert, the innovative company behind the cannabis composition and potency testing “lab-on-a-desk,” today announced the opening of a new funding round seeking to raise an additional $5-6 million (US) to help the company advance the commercialization of its groundbreaking testing solution and visionary product roadmap. To date, the company has raised just over $3 million (US) including investors from a number of investors, including European-based NEO Ventures Inc., Beverly Hills-based Applied Biosciences Corp., and Tel Aviv-based Arba Finance Company Ltd.
GemmaCert delivers a unique hybrid testing solution that combines leading-edge near-infrared spectroscopy (NIRS) technology with visual image analysis, extensive data science, and machine learning. Food and Drug Administration (FDA)-endorsed NIRS is a scientific measurement technique that measures how the near-infrared region of the electromagnetic spectrum is emitted, absorbed, or scattered through a cannabis sample.
Grinding is never required and testing doesn’t use solvents or any consumables, eliminating the need for sample preparation and disposal of hazardous waste. Additionally, the GemmaCert process never destroys the sample, preserving both efficacy and commercial value. Simply place whole flower bud into the GemmaCert lab-on-a-desk and an accurate analysis returns within a few minutes. Captured data is sent via a network connection to secure servers in the cloud for quick analysis, with results sent to the tester via a smartphone app.
Pre-orders for the GemmaCert device have been coming in from around the world, including U.S., Canada, Switzerland, New Zealand and Israel. Early adopters can secure a GemmaCert device for only a 10 percent down payment. Pre-orders can be placed online at: http://gemmacert.com/index.php/shop/. First units will be shipped to early adopters during the coming weeks.
“GemmaCert originally developed our testing technology for patients that depend on home- or smaller-grow operations, but were blind to the quality and potency of their medicine,” said Guy Setton, CEO and co-founder of GemmaCert. “As we demonstrated our technology across the industry, we discovered the need for access to highly-accurate test results, even if they are not from a certified lab. For instance, commercial cultivators and processors want to use GemmaCert for internal quality control, research and development, as well as transactional purposes.”
New funds from this funding round will be used to fund the company’s aggressive product roadmap and vision, as well as boost marketing and sales efforts. New features are currently being engineered for the software-updatable GemmaCert testing device, which will deliver new capabilities to these original units. The company also has plans to integrate its NIRS technology into commercial cannabis grow and manufacturing operations.
Investors interested in speaking to GemmaCert can contact the company at: email@example.com.
GemmaCert is a private biotechnology company, based in Israel since 2015, aiming to become a market leader in cannabis composition and potency analysis. GemmaCert’s skilled team of chemists, molecular biologists, biotechnologists, data scientists, and programmers work tirelessly to advance cannabis analytical solutions. In the long run, GemmaCert’s breakthrough technology will enable patients and doctors to correlate cannabis composition with specific health conditions, significantly enhancing therapeutic treatment by cannabis and transforming the medical cannabis industry. To date, the company has raised over $3M in funding and continues to push the boundaries of cannabis technology everywhere. For more information visit www.gemmacert.com.
# # #